MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

Download PDF Copy

Apr 7 2010

NewsGuard 100/100 Score

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia. The data will be presented at the Annual Meeting of the American Academy of Neurology (AAN) in Toronto, Ontario on Wednesday, April 14, 2010.

Source:

MAP Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News | Women's Health News

Tags: Allodynia, Cancer, Headache, Migraine, Nausea, Neurology, Pharmaceuticals, Vomiting

Comments (0)

Download PDF Copy

Suggested Reading

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

SU2C announces grants to support cutting-edge research in a variety of cancers

SU2C announces grants to support cutting-edge research in a variety of cancers

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Urine RNA analysis shows promise for detecting genitourinary diseases